104 related articles for article (PubMed ID: 3476764)
1. [Treatment of hypoplastic leukemia--clinical effects of low-dose 4N-behenoyl-beta-D-arabinofuranosylcytosine (BH-AC) therapy].
Nakada H; Takahashi I; Yorimitu S; Hara M; Ohmoto E; Inagaki T; Aoyama S; Nishimura M; Hayashi N; Sekito N
Rinsho Ketsueki; 1987 Apr; 28(4):534-40. PubMed ID: 3476764
[No Abstract] [Full Text] [Related]
2. [Low-dose 4N-behenoyl-1-beta-D-arabinofuranosylcytosine (BHAC) in the treatment of atypical leukemia].
Takahashi I; Nakada H; Hayashi N; Sekito N; Inagaki T; Aoyama S; Nonaka K; Ohmoto E; Kobayashi Y; Uchida K
Gan To Kagaku Ryoho; 1986 Sep; 13(9):2780-5. PubMed ID: 3463249
[TBL] [Abstract][Full Text] [Related]
3. [Pharmacokinetic studies of N4-behenoyl-1-beta-D-arabinofuranosylcytosine (BH-AC) by 30-minute infusion with acute nonlymphocytic leukemia--the possibility of administration for outpatients].
Hirosawa S
Gan To Kagaku Ryoho; 1988 Jun; 15(6):1991-3. PubMed ID: 3164182
[No Abstract] [Full Text] [Related]
4. Effects of N4-behenoyl-1-beta-D-arabinofuranosylcytosine on blast progenitors of acute myeloblastic leukemia.
Nara N; Tohda S; Suzuki T; Nagata K; Yamashita Y; Imai Y; Maruyama Y; Tomiyama J
Cancer Res; 1990 Dec; 50(23):7587-92. PubMed ID: 2253209
[TBL] [Abstract][Full Text] [Related]
5. Induction chemotherapy with idarubicin plus N4-behenoyl-1-beta-D-arabinofuranosylcytosine in acute myelogenous leukemia: a newly designed induction regimen--a prospective, cooperative multicenter study.
Park HS; Kim DW; Kim CC; Kim HK; Kim JS; Hwang TJ; Kim HJ; Kim HS; Song HS; Park JW; Ahn HS; Chung TJ; Cho KS; Lee KS; Choi YM
Semin Hematol; 1996 Oct; 33(4 Suppl 3):24-9. PubMed ID: 8916313
[TBL] [Abstract][Full Text] [Related]
6. [Clinical and pharmacokinetic studies of high dose N4-behenoyl-1-beta-D-arabinofuranosylcytosine].
Yoshida T; Nakamura S; Ohtake S; Ito K; Kobayashi K; Kanno M; Hirai J; Tachimori K; Matsuda T
Gan To Kagaku Ryoho; 1987 Jun; 14(6 Pt 1):1820-4. PubMed ID: 3592717
[TBL] [Abstract][Full Text] [Related]
7. [Treatment of malignant lymphoma with single administration of BH-AC (N4-behenoyl-1-beta-D-arabinofuranosylcytosine].
Oguro M; Takagi T
Gan To Kagaku Ryoho; 1982 Mar; 9(3):508-15. PubMed ID: 6764108
[TBL] [Abstract][Full Text] [Related]
8. [Successful treatment with a small dose of N4-behenoyl-1-beta-D-arabinofuranosylcytosine in a case of chronic myelomonocytic leukemia in blastic crisis].
Tsukada J; Misago M; Sato T; Kikuchi M; Nakata K; Nagata K; Mori N; Otani H; Oda S; Chiba S
Rinsho Ketsueki; 1989 Jan; 30(1):61-6. PubMed ID: 2716200
[TBL] [Abstract][Full Text] [Related]
9. [Pharmacokinetics of N4-behenoyl-1-beta-D-arabinofuranosylcytosine after intraperitoneal administration].
Noda T; Oku M; Kiyozuka Y; Maruyama M; Adachi S; Akada S; Okamura Y; Ichijo M
Gan To Kagaku Ryoho; 1988 Oct; 15(10):2929-35. PubMed ID: 3178241
[TBL] [Abstract][Full Text] [Related]
10. [Treatment of acute leukemia with newly synthesized N4-behenoyl-l-beta-D-arabinofuranosylcytosine (BH-AC) (author's transl)].
Sueyama H; Oguro M; Takagi T
Rinsho Ketsueki; 1981 Jul; 22(7):1109-15. PubMed ID: 7328768
[No Abstract] [Full Text] [Related]
11. [Combination chemotherapy of N(4)-behenoyl-1-beta-arabinofuranosylcytosine, aclarubicin, 6-MP, and prednisolone (BH-AC. AMP therapy) for adult acute non-lymphocytic leukemia].
Ishige K; Takagi T; Oguro M
Gan To Kagaku Ryoho; 1984 Jul; 11(7):1475-9. PubMed ID: 6588925
[TBL] [Abstract][Full Text] [Related]
12. Cytotoxicity of N4-behenoyl-1-beta-D-arabinofuranosylcytosine through gradual conversion to 1-beta-D-arabinofuranosylcytosine in HeLa cells.
Maehara Y; Kusumoto T; Sakaguchi Y; Kusumoto H; Anai H; Sugimachi K
Anticancer Res; 1989; 9(1):41-4. PubMed ID: 2705754
[TBL] [Abstract][Full Text] [Related]
13. ["A-triple-V" in refractory or relapsed acute myelocytic leukemia].
Miyawaki S; Nemoto K; Wakamatsu R; Baba N; Yashiro K; Uchida S; Nakura M; Karasawa M; Takada M; Tanaka H
Rinsho Ketsueki; 1987 Jan; 28(1):34-9. PubMed ID: 3471982
[No Abstract] [Full Text] [Related]
14. [Early phase II study of PL-AC [N4-palmitoyl-(1-beta-D-arabinofuranosyl) cytosine] on hematopoietic malignancies].
Takubo T; Kubota Y; Tanaka T; Ueda T; Shibata H; Nakamura H; Masaoka T; Yoshitake J; Ishigami S
Gan To Kagaku Ryoho; 1983 Feb; 10(2 Pt):283-9. PubMed ID: 6576729
[TBL] [Abstract][Full Text] [Related]
15. [Treatment of acute myeloid leukemia with an intense chemotherapeutic regimen and variable reduction of the dosage for elderly patients].
Whittaker JA
Clin Ter; 1982 Sep; 102(5):435-41. PubMed ID: 6960975
[No Abstract] [Full Text] [Related]
16. [Remission induction by ACM-A and BH-AC on acute promyelocytic leukemia which is resistant to DNR and CA (author's transl)].
Shimazaki C; Nakajima Y; Ura Y; Hamami T; Haruyama H; Isemura T; Nakagawa M; Ijichi H
Rinsho Ketsueki; 1981 Jul; 22(7):1116-22. PubMed ID: 6948970
[No Abstract] [Full Text] [Related]
17. Phase III study of N4-behenoyl-l-beta-D-arabinofuranosylcytosine in adult acute leukemia-BH-AC-DMP therapy.
Yamada K; Suzuki H; Kato Y
Nihon Ketsueki Gakkai Zasshi; 1980 Dec; 43(6):1080-5. PubMed ID: 7331685
[No Abstract] [Full Text] [Related]
18. Tallimustine, an effective antileukemic agent in a severe combined immunodeficient mouse model of adult myelogenous leukemia, induces remissions in a phase I study.
Beran M; Jeha S; O'Brien S; Estey E; Vitek L; Zurlo MG; Rios MB; Keating M; Kantarjian H
Clin Cancer Res; 1997 Dec; 3(12 Pt 1):2377-84. PubMed ID: 9815637
[TBL] [Abstract][Full Text] [Related]
19. Idarubicin plus continuous-infusion high-dose cytarabine as treatment for patients with acute myelogenous leukemia or myelodysplastic syndrome.
Estey EH; Kantarjian H; Keating M
Semin Oncol; 1993 Dec; 20(6 Suppl 8):1-5. PubMed ID: 8290966
[TBL] [Abstract][Full Text] [Related]
20. Relapse and death during first remission in acute myeloid leukemia.
Yanada M; Garcia-Manero G; Borthakur G; Ravandi F; Kantarjian H; Estey E
Haematologica; 2008 Apr; 93(4):633-4. PubMed ID: 18379012
[No Abstract] [Full Text] [Related]
[Next] [New Search]
